---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066933"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:04:35.236499+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility

## Summary
- Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.
- Cash $104.7M at Mar 31, 2025, down from $152.5M; non-GAAP cash burn $46.6M; runway into 2026.
- Positive 12-week data for UP421 (HIP islet cells) in T1D: C-peptide production, immune evasion without immunosuppression.
- Enrolling GLEAM (autoimmune) and VIVID (B-cell malignancies) trials; expect data in 2025.
- New at-the-market (ATM) agreement with TD Cowen to sell up to $119M of common stock.

## SEC filing metadata
- accession: 0000950170-25-066933
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/0000950170-25-066933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/sana-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066933
- JSON: https://secwatch.observer/filing/0000950170-25-066933.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.